|
Classes |
Anti cancer drugs |
|
Angiogenesis inhibitors |
• Bevacizumab • Sunitinib • Sarafenib |
|
BCR-ABL tyrosine kinase inhibitors |
1st Generation- • Imatinib
2nd Generation (for imatinib resistant CML pt)- • Dasatinib • Nilotinib
3rd Generation (for T315I mutated CML pt)- • Ponatinib |
|
CD20 inhibitor |
• Rituximab |
|
EGF receptor inhibitor |
HER-1 inhibitor: • Gefitinib • Erlotinib • Cetuximab
HER-2 inhibitor: • Transtizumab • Lapatinib |
|
EGF receptor (HER-1) inhibitor |
• Transtizumab • Lapatinib |
|
Proteasome inhibitor |
• Bortezomib |
|
mTOR inhibitors |
• Everolimus (oral) • Temsirolimus (iv) |
Imatinib use-
BCR-ABL mutation:
• Acute lymphoblastic leukemia (ALL)
• Chronic myelogenous leukemia (CML)
c-kit mutation:
• GIST (Gastrointestinal stromal tumor)
Platelet derived growth factor receptor (PDGFR) mutation:
• Dermatofibrosarcoma protuberans